sermorelin-peptide-oral The dominant search intent for "foxo4-dri peptide senolytic" is to understand what the FOXO4-DRI peptide is, how it functions as a senolytic agent, and its potential applications, particularly in relation to cellular aging and senescent cells.Targeted Apoptosis of Senescent Cells Restores Tissue ...
Tier 1:
* Core Entities: FOXO4-DRI peptide, senolytic, senescent cells
* High-Relevance Phrases: selectively removes senescent cells, induces apoptosis, blocks the interaction of FOXO4 and p53, cell-permeable peptide antagonist
Tier 2:
* Supporting Entities/Concepts: FOXO4, p53, apoptosis, cellular aging, fibroblasts, chondrocytes, cancer cells, healthspan, lifespan, retro-inverso peptide
* Attributes/Functions: targets p53, promotes apoptosis, removes senescent cells, anti-aging, novel senolytic, therapeutic
* Variations: FOXO4-D-retro-inverso, FOXO4-DRI acetate
Tier 3:
* Specific research paper titles, highly technical chemical formulas, CAS numbers, vendor-specific product codes, repetitive mentions of "peptide" without context.
---
The FOXO4-DRI peptide has emerged as a significant agent in the field of cellular aging, functioning as a senolytic compound作者：YX Kong·2025·被引用次数：9—We further demonstrate that asenolyticFOXO4-D-retro-inverso-isoformpeptide(FOXO4-DRI) promotes apoptosis and decreases G0/G1 phase cells in .... Its primary mechanism involves the selective elimination of senescent cells, a process that holds considerable promise for combating age-related decline and diseases.FOXO4-DRI是一种细胞渗透性肽拮抗剂，可阻断FOXO4 和p53 的相互作用。FOXO4-DRI是一种抗衰老多肽，可诱导衰老细胞凋亡(apoptosis)。- 高纯度，全球文献引用。 As a cell-permeable peptide antagonist, FOXO4-DRI is designed to block the interaction of FOXO4 and p53, key proteins involved in cellular stress responses and aging. This targeted action leads to the induction of apoptosis, or programmed cell death, specifically in senescent cells, while largely sparing healthy cells.
Cellular senescence is a state where cells stop dividing but remain metabolically active, often accumulating with age.FOXO4-DRIis asenolytic peptidethat induces apoptosis of senescent cells. Product Information. Catalog Num, A22834. Formula, C228H388N86O64. Molecular Weight ... These senescent cells contribute to tissue dysfunction and inflammation through the secretion of various factors, collectively known as the senescence-associated secretory phenotype (SASP)US20200255489A1 - Novel Senolytic Peptides. Senolytics are a class of drugs or compounds designed to clear these harmful senescent cellsUsing research pioneered by Dr. Patrick de Keizer, Cleara Biotech is developing asenolytic peptidecalledFOXO4-DRI, which does not harm healthy cells.. The FOXO4-DRI peptide represents a novel approach in this area, offering a precise method for targeting and removing these aged cells.Senolytic Peptide FOXO4-DRI Selectively Removes ... - PubMed
The efficacy of FOXO4-DRI lies in its ability to disrupt the critical interaction between the FOXO4 transcription factor and the tumor suppressor protein p53. In senescent cells, this interaction can lead to a survival advantage. By acting as a peptide antagonist, FOXO4-DRI interferes with this complex, thereby promoting the apoptotic pathways that senescent cells often evade. This targeted disruption is crucial for its senolytic activityFOXO4-DRI induces keloid senescent fibroblast apoptosis by .... Research indicates that FOXO4-DRI can effectively induce apoptosis in various senescent cell types, including fibroblasts and chondrocytes, and has shown potential in preclinical models for eliminating senescent cancer cells.
The senolytic properties of FOXO4-DRI suggest a wide range of potential applications in promoting healthspan and addressing age-related conditions. Studies have demonstrated its ability to selectively remove senescent cells from in vitro expanded human chondrocytes, hinting at possibilities for regenerative medicine and tissue repair. Furthermore, research has indicated that FOXO4-DRI can alleviate age-related testosterone secretion insufficiency by improving the testicular microenvironment in aged mice, underscoring its potential impact on hormonal balance and reproductive health in aging populations. Its targeted nature, focusing on senescent cells without harming healthy ones, makes it an attractive candidate for therapeutic development in areas such as age-related diseases, fibrosis, and potentially even cancer therapy by clearing senescent tumor cells.作者：Y Huang·2021·被引用次数：51—FOXO4-DRIis able to remove the senescent cells in PDL9 chondrocytes, but its utility in promoting cartilage formation from the in vitro expanded chondrocytes ...
While the FOXO4-DRI peptide shows significant promise as a senolytic agent, ongoing research is crucial to fully elucidate its therapeutic potential and safety profile.Senolytic Peptide Foxo4-DriSelectively Removes Senescent Cells From In Vitro Expanded Human Chondrocytes. Clinical trials will be essential to determine optimal dosages, delivery methods, and long-term effects in humans. Understanding potential off-target effects and the precise molecular pathways involved in its action will further refine its application. As a cutting-edge senolytic peptide, FOXO4-DRI represents a significant advancement in the quest to manage cellular aging and improve overall health in later life.
Join the newsletter to receive news, updates, new products and freebies in your inbox.